Document is current
Any future updates will be listed below
-
Authors
Maruyama, Dai https://orcid.org/0000-0003-0654-6920
Yoshimitsu, Makoto
- License Information
-
More Information
Article History
Received: 29 April 2025
Revised: 29 April 2025
Accepted: 19 May 2025
First Online: 12 June 2025
Declarations
:
: DM has received per diem, including speaking fees, from Janssen Pharmaceutical, Chugai Pharmaceutical, Kyowa Kirin, Eisai, AstraZeneca, SymBio Pharmaceuticals, and Takeda Pharmaceuticals; and has received research funding from Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceuticals, Janssen Pharmaceutical, MSD, Loxo Oncology, Bristol Myers Squibb, Kyowa Kirin, Otsuka Pharmaceutical, and IQVIA Services Japan. MY has no conflicts of interest to report.
